| Value | Category | Cases | |
|---|---|---|---|
| trastuzumab | Trastuzumab | 42 |
22.7%
|
| pertuzumab | Pertuzumab | 62 |
33.5%
|
| other | Other | 51 |
27.6%
|
| not_available | Not available/Non-applicable | 30 |
16.2%
|